Research Signal – Source date 2022-11-29
Sleep problems and cognitive decline meet in an important research question for people in the early stages of Alzheimer’s disease. Are changes in sleep related to changes in memory, and could sleep measures help identify people whose cognition is beginning to worsen?
A ClinicalTrials.gov record dated November 29, 2022 describes a study designed to investigate that relationship. The study follows participants over two years, collecting detailed sleep measurements alongside repeated cognitive assessments. It is a plan for gathering evidence, not a report that a relationship has already been observed.
A question about sleep and early memory change
The registry description starts from a possible connection between the accumulation of β-amyloid peptides in the brain and deteriorating sleep. It presents that connection as unresolved. The study’s aim is to examine whether sleep disorders and cognitive decline are related in people being studied in the context of early Alzheimer’s disease.
That question requires more than asking participants whether they slept well. Researchers need measurements that describe sleep itself and assessments that show how memory and other cognitive abilities change. The study therefore treats sleep and cognition as paired observations collected from the same people over time.
Two kinds of evidence collected together
Polysomnography is a detailed recording of sleep-related activity. In this study, the registry describes 24-hour polysomnography at inclusion and again at 24 months. The recorded outcomes include time spent in different sleep stages, rapid eye movement sleep, breathing interruptions during sleep and nighttime oxygen saturation.
Those recordings are paired with neuropsychological assessments at inclusion, 12 months and 24 months. The primary memory measure is the Free and Cued Selective Reminding Test, while the registry also lists a composite assessment of cognitive decline. In practical terms, the sleep recordings describe how a participant’s sleep is organized, while the cognitive assessments provide repeated measures of memory and broader performance.
The protocol also describes 14-day activity monitoring, sleep and behavior questionnaires, measurements related to melatonin and internal temperature, and assays of Alzheimer’s-related proteins in blood and cerebrospinal fluid. These additional observations can add context to the central comparison without turning any one measurement into a diagnosis by itself.
Why the schedule matters
The timing creates a series of within-person observations. Sleep is measured at the beginning and end of the two-year follow-up, while cognition is assessed at the beginning, midway point and 24 months. The midpoint cognitive assessment can show how performance is changing before the final sleep recording is made.
Researchers can then compare each participant’s sleep-related measures with changes in memory and cognitive scores over the same period. The important comparison is not simply whether one person sleeps differently from another. It is whether patterns of sleep and changes in cognition are related across follow-up, using observations taken at defined points after each participant joins the study.
The dates attached to the overall registry record are different from those participant-level intervals. The snapshot lists an actual study start date of April 17, 2023 and gives July 1, 2027 as an estimated primary and overall completion date. Those calendar dates describe the study’s broader timeline; they do not replace the inclusion, 12-month and 24-month schedule for individual participants.
A diagnostic design, not a treatment trial
The registry classifies the study as interventional, single-group and diagnostic, with estimated enrollment of 132 people. In the described design, participants undergo measurements and assessments rather than being assigned to different sleep treatments. There is no treatment comparison in the listed single-arm structure.
That matters for interpreting the eventual findings. A relationship between a sleep pattern and cognitive change could make the pattern worth monitoring in early Alzheimer’s disease. It would not, by itself, show that treating a sleep disorder slows Alzheimer’s disease or preserves memory. Establishing that possibility would require evidence that changing sleep through an intervention changes cognitive outcomes.
The supplied registry snapshot does not provide results from this study. Estimated enrollment is a planning figure, and scheduled assessments do not show how many participants ultimately completed them. For now, the record supports a clear account of the question and the measurements intended to address it.
What this could change
For people with early Alzheimer’s disease, recognizing sleep disturbances that are linked to subsequent cognitive change could make sleep assessment more useful in their care. It could give clinicians another practical dimension to follow alongside memory and other cognitive measures.
The registry also raises a longer-term possibility: earlier treatment of sleep disorders might help slow disease development. That benefit would depend on future evidence that treating sleep changes cognitive outcomes, beyond identifying an association between sleep and memory change.
Key Sources
- Primary source: Biomarkers of Sleep-wake Cycle in Prodromal Alzheimer's Disease: Role in Cognitive Decline?
Government or Regulator · Clinical Trial · 2022-11-29
Keep exploring